-
公开(公告)号：US20110097404A1
公开(公告)日：2011-04-28
申请号：US12909614
申请日：2010-10-21
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
IPC分类号： A61K9/16 , A61K31/4355
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.
摘要翻译： 公开了一种口服剂型，其包含（i）可释放形式的阿片样物质激动剂和（ii）当剂型口服完整时不释放的螯合阿片样物质拮抗剂。
-
公开(公告)号：US20080306104A2
公开(公告)日：2008-12-11
申请号：US10700893
申请日：2003-11-04
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
IPC分类号： A61K31/485 , A61K9/22
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
-
公开(公告)号：US20080305167A2
公开(公告)日：2008-12-11
申请号：US10700906
申请日：2003-11-04
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
摘要翻译： 公开了一种口服剂型，其包含（i）可释放形式的阿片样物质激动剂和（ii）隔离的阿片样物质拮抗剂，当所述剂型完全施用时基本上不释放，使得从所述剂量释放的拮抗剂的量的比例 基于在使用USP II型的900ml模拟胃液中的所述剂型在1小时时的体外溶出，篡改之后从所述完整剂型释放的所述拮抗剂的量为约4:1或更大 桨）装置，其在37℃下以75rpm的速度进行，其中所述激动剂和拮抗剂是分散的并且在两个不同的层中不彼此分离。
-
公开(公告)号：US08236351B2
公开(公告)日：2012-08-07
申请号：US12909614
申请日：2010-10-21
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.
摘要翻译： 公开了一种口服剂型，其包含（i）可释放形式的阿片样物质激动剂和（ii）当剂型口服完整时不释放的螯合阿片样物质拮抗剂。
-
公开(公告)号：US07842311B2
公开(公告)日：2010-11-30
申请号：US10689866
申请日：2003-10-21
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/24 , A61K9/28 , A61K9/48 , A61K9/52 , A61K9/54
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
-
公开(公告)号：US07658939B2
公开(公告)日：2010-02-09
申请号：US10701041
申请日：2003-11-04
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
IPC分类号： A61K9/20 , A61K9/48 , A61K31/135 , A61K31/485
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
-
公开(公告)号：US20080311198A2
公开(公告)日：2008-12-18
申请号：US10700861
申请日：2003-11-04
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
-
公开(公告)号：US06696088B2
公开(公告)日：2004-02-24
申请号：US09781081
申请日：2001-02-08
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
IPC分类号： A61K920
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.
-
公开(公告)号：US20120288565A1
公开(公告)日：2012-11-15
申请号：US13544333
申请日：2012-07-09
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
IPC分类号： A61K9/00 , A61K9/14 , A61P25/04 , A61K31/485
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.
摘要翻译： 公开了口服剂型，其包含：（i）可释放形式的阿片样物质激动剂和（ii）当所述剂型口服完整时不释放的螯合阿片样物质拮抗剂。
-
公开(公告)号：US07842309B2
公开(公告)日：2010-11-30
申请号：US10700861
申请日：2003-11-04
申请人： Benjamin Oshlack , Curtis Wright , J. David Haddox
发明人： Benjamin Oshlack , Curtis Wright , J. David Haddox
CPC分类号： A61K9/5084 , A61K9/0043 , A61K9/0053 , A61K9/006 , A61K9/02 , A61K9/14 , A61K9/1617 , A61K9/1635 , A61K9/1647 , A61K9/1676 , A61K9/1694 , A61K9/2077 , A61K9/2081 , A61K9/2866 , A61K9/4808 , A61K9/50 , A61K9/501 , A61K9/5015 , A61K9/5026 , A61K9/5031 , A61K9/5078 , A61K9/51 , A61K9/7053 , A61K9/7061 , A61K31/485
摘要： Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact.
摘要翻译： 公开了一种口服剂型，其包含（i）可释放形式的阿片样物质激动剂和（ii）当所述剂型完整施用时基本上不释放的螯合阿片样物质拮抗剂。
-
-
-
-
-
-
-
-
-
搜索结果
123 条记录 (耗时 0.039 秒)
